Introduction
============

Non-alcoholic fatty liver disease (NAFLD) covers a range of liver disorders originating from excessive lipid, mainly triglyceride, accumulation in the liver ([@ddy124-B1]). Fatty liver has been proposed to result in dyslipidemia due to increased secretion of very low-density lipoproteins (VLDL) and impaired clearance of intermediate and low-density lipoproteins (IDL, LDL) from circulation ([@ddy124-B2],[@ddy124-B3]). Studies using detailed metabolic profiling have shown that fatty liver associates with multiple metabolic aberrations in circulation ([@ddy124-B4]). In a study by Kaikkonen *et al.*, fatty liver associated most prominently with triglycerides in the largest VLDL particle subfractions as well as with VLDL particle concentration, but robust associations were also seen with many non-lipid traits, such as amino acids leucine and isoleucine ([@ddy124-B4]). Animal models and human studies have shown that liver fat content correlates with levels of blood lipids and glucose ([@ddy124-B7]). However, fatty liver does not always seem to relate to dyslipidemia or changes in glycemic traits ([@ddy124-B10],[@ddy124-B11]) and thus its effect on metabolic changes in circulation has remained unclear.

Genetic factors contribute to the pathogenesis of fatty liver. Four DNA sequence variants, Patatin-like phospholipase domain containing 3 (*PNPLA3*) rs738409-G, Glucokinase regulator (*GCKR*) rs780094-T, Neurocan (*NCAN*) rs2228603-T and Lysophospholipase-like 1 (*LYPLAL1*) rs12137855-C, were associated with computed tomography defined steatosis and biopsy-proven NAFLD involving lobular inflammation and fibrosis in a large-scale genome-wide association study (GWAS) ([@ddy124-B12]). Other studies have shown that *GCKR* rs1260326-T and Transmembrane 6 superfamily member 2 (*TM6SF2*) rs58542926-T are the functional variants at the *GCKR* and *NCAN* loci, respectively ([@ddy124-B13]). *PNPLA3* rs738409-G is the strongest genetic risk factor for NAFLD ([@ddy124-B16]) having an odds ratio of 3.24 for histologic NAFLD ([@ddy124-B12]). *GCKR* rs1260326-T and *TM6SF2* rs58542926-T are also recognized as important determinants of inter-individual variation in liver fat ([@ddy124-B13],[@ddy124-B17],[@ddy124-B18]). Among these variants, the function of *LYPLAL1* rs12137855-C is the least known.

In the present study, we perform metabolic profiling of ultrasound-ascertained fatty liver in young and middle-aged adults. To add insights into molecular mechanisms of fatty liver-related metabolic aberrations, we compare how the observational fatty liver associations match with metabolic association profiles of the aforementioned NAFLD risk alleles. We utilize publicly available summary statistics from a metabolomics GWAS to assess the detailed metabolic effects of the risk variants ([@ddy124-B19]). Understanding the relation between fatty liver and changes in circulating lipids and metabolites is helpful in acquiring more opportunities for treatment and prevention of this complex condition and related cardiometabolic complications. Cardiovascular disease is the leading cause of death in patients with fatty liver ([@ddy124-B20]) emphasizing the need of effective management of cardiovascular health in these individuals.

Results
=======

Fatty liver and circulating metabolites
---------------------------------------

Characteristics of the YFS study population are shown in [Table 1](#ddy124-T1){ref-type="table"}. Fatty liver showed association with 84 metabolic measures (*P* \< 0.0004) when adjusted with age, sex and 10 genetic principal components ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 1; [Supplementary Material, Figs S2 and S3; Table S2](#sup1){ref-type="supplementary-material"}). Lipoprotein subclass concentrations showed a trend where the largest VLDL particles displayed the most pronounced associations that got weaker while the particle size decreased, and again stronger for medium and small LDL particles ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 1). Concentration of very large and large HDL particles showed negative association with fatty liver, while small HDL particles displayed a strong positive association. Fatty liver associated with increased VLDL diameter while the associations with LDL and HDL particle diameters were negative. Fatty liver showed positive association with apolipoprotein B concentration. Concentrations of serum total triglycerides and triglycerides in all lipoprotein subclasses except very large HDL were increased in association with fatty liver. Concentrations of circulating total fatty acids, PUFA, MUFA, and omega-7, -9, and other saturated fatty acids, and level of fatty acid saturation were increased in association with fatty liver, while its association with fatty acid length was negative. In addition, fatty liver displayed positive association with glucose, lactate, pyruvate and glycerol, as well as with amino acids alanine, isoleucine, leucine, valine, phenylalanine and tyrosine. Association between fatty liver and amino acid glutamine was negative. Table 1.Study population: YFSFatty liverNo fatty liverTotal population*N*33814721810Male (%)237 (70.1)630 (42.8)867 (47.9)BMI, kg/m^2^30.5 ± 5.325.5 ± 4.326.4 ± 4.9Age, years43.0 ± 4.741.6 ± 5.041.9 ± 5.0Smokers (%)55 (16.3)198 (13.5)253 (14.0)Alcohol consumption per day[^a^](#tblfn1){ref-type="table-fn"}2.13 ± 1.81.87 ± 1.61.92 ± 1.6[^1][^2]

![Cross-sectional associations of fatty liver with lipoprotein particle subfraction concentrations, lipoprotein particle diameter, apolipoproteins, triglycerides, fatty acids, fatty acid saturation, beta-oxidation, glycolysis, amino acid-related metabolites and inflammation marker GlycA, and the corresponding associations with four NAFLD risk alleles. Cross-sectional associations were determined in 1, 810 adults aged 34--49 years of whom 338 were diagnosed with ultrasound-based fatty liver. The metabolic phenotypes were adjusted for age, sex, and 10 first genetic principal components prior to analysis. Genetic effects of the NAFLD risk alleles *GCKR* rs1260326-T, *LYPLAL1* rs12137855-C, *PNPLA3* rs738409-G and *TM6SF2* rs58542926-T were acquired from a metabolomics GWAS including up to 24 925 Europeans ([@ddy124-B19]). Genetic effect estimates were scaled with respect to the NAFLD risk associated with the corresponding locus ([@ddy124-B12]). VLDL, very low-density lipoprotein; IDL, intermediate density lipoprotein; HDL, high density lipoprotein; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; GlycA, glycoprotein acetylation.](ddy124f1){#ddy124-F1}

The analysis further adjusted for alcohol consumption resulted in practically identical association profile with the primary analysis ([Supplementary Material, Fig. S2](#sup1){ref-type="supplementary-material"}). Adjustment for BMI attenuated the effect estimates, as expected, but the overall association pattern was similar to the primary analysis ([Supplementary Material, Fig. S2](#sup1){ref-type="supplementary-material"}).

NAFLD risk alleles in *GCKR* and *LYPLAL1* tend to increase concentrations of circulating lipids
------------------------------------------------------------------------------------------------

The studied NAFLD risk increasing alleles showed different association profiles on metabolic measures. The association profile of *GCKR* rs1260326-T was similar to the one of fatty liver especially in terms of circulating lipids and lipoproteins ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 2; [Supplementary Material, Fig. S3; Table S3](#sup1){ref-type="supplementary-material"}). However, some mismatches were observed. Glucose concentration showed a tenuous decrease in association with *GCKR* rs1260326-T while it was increased in association with fatty liver. Concentrations of amino acids phenylalanine and tyrosine showed no robust associations with *GCKR* rs1260326-T but were increased in association with fatty liver. Lipoprotein association profiles of the *GCKR* rs1260326-T and fatty liver differed in terms of very large and large HDL particle subfraction concentration and lipid composition: the particle concentration of the two HDL subfractions together with all lipids except triglycerides in these subfractions showed only negligible reduction in association with *GCKR* rs1260326-T but were highly decreased in association with fatty liver ([Supplementary Material, Fig. S3](#sup1){ref-type="supplementary-material"}). Concentration of apolipoprotein A-I was increased in the *GCKR* risk allele carriers, while it showed a small reduction in association with fatty liver. Some differences were also observed in concentrations of omega-3 fatty acids, docosahexaenoic acid, omega-6 fatty acids and linoleic acid. The results of *GCKR* rs780094-T, a variant originally identified as a NAFLD risk allele in the GCKR locus ([@ddy124-B12]) being in linkage disequilibrium with the functional *GCKR* rs1260326-T ([@ddy124-B13]) matched well with the results of *GCKR* rs1260326-T ([Supplementary Material, Figs S1 and S3; Table S3](#sup1){ref-type="supplementary-material"}).

The association profile of *LYPLAL* rs12137855-C was similar to the metabolic effects of *GCKR* rs1260326-T in terms of highly correlated point estimates of the two risk alleles ([Supplementary Material, Fig. S4](#sup1){ref-type="supplementary-material"}), but the effects of *LYPLAL* rs12137855-C were statistically less robust and the effect magnitudes were weaker than for the *GCKR* variant ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 3; [Supplementary Material, Fig. S3; Table S3](#sup1){ref-type="supplementary-material"}). The high correlation of the metabolic effects suggests that LYPLAL1 may function on a related biological pathway with GCKR.

*PNPLA3* rs738409-G does not show association with circulating metabolic traits
-------------------------------------------------------------------------------

*PNPLA3* rs738409-G, the strongest genetic contributor to the hepatic fat content ([@ddy124-B16]), displayed metabolic association profile close to null ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 4; [Supplementary Material, Fig. S3; Table S3](#sup1){ref-type="supplementary-material"}). When compared with the fatty liver effects, the NAFLD risk scaled metabolic effects of *PNPLA3* rs738409-G were much closer to zero, and the confidence intervals for effect estimates of cross-sectional fatty liver and *PNPLA3* rs738409-G were clearly separated.

*TM6SF2* rs58542926-T associates with lower-risk lipoprotein lipid profile and lower glycoprotein acetylation
-------------------------------------------------------------------------------------------------------------

*TM6SF2* rs58542926-T displayed strong association profile in particular on the lipoprotein lipid traits ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 5; [Supplementary Material, Fig. S3; Table S3](#sup1){ref-type="supplementary-material"}). However, the associations were negative indicating lower concentrations of the lipids and metabolites in relation to higher NAFLD risk. The *TM6SF2* variant associated with lower concentrations of all the VLDL, IDL and LDL particle subclasses and all the lipid species in these subclasses. In addition, the variant associated inversely with serum total triglycerides and triglycerides in all the lipoprotein subclasses including the HDL subclasses. The variant associated with smaller VLDL particle diameter, while it did not show an effect on LDL nor HDL particle size. The *TM6SF2* rs58542926-T associated with lower concentration of the apolipoprotein B but did not influence concentration of apolipoprotein A-I. It associated inversely also with all the fatty acid concentrations, while the qualitative measures such as fatty acid length or saturation measures were not influenced by this variant. In addition, the T allele associated with lower levels of glycerol and glycoprotein acetylation, a marker for inflammation ([@ddy124-B21]). The results for *NCAN* rs2228603-T in the same NAFLD risk locus can be found in the supplement ([Supplementary Material, Figs S1 and S3; Table S3](#sup1){ref-type="supplementary-material"}).

Resemblance of the metabolic effects
------------------------------------

The correspondence between the metabolic effects of the risk alleles and observational fatty liver was the highest between the *GCKR* rs1260326-T and fatty liver (*R*^2^ = 0.77; [Fig. 2C](#ddy124-F2){ref-type="fig"}). The remaining coefficients of determination were *R*^2^ = 0.67 for *LYPLAL1* rs12137855-C versus fatty liver ([Fig. 2D](#ddy124-F2){ref-type="fig"}), *R*^2^ = 0.45 for *TM6SF2* rs58542926-T versus fatty liver ([Fig. 2B](#ddy124-F2){ref-type="fig"}) and *R*^2^ = 0.30 for *PNPLA3* rs738409 G versus fatty liver ([Fig. 2A](#ddy124-F2){ref-type="fig"}).

![The overall match between the metabolic effects of the NAFLD risk alleles and fatty liver. The black dashed line shows the linear fit between metabolic changes associated with fatty liver and *PNPLA3* rs738409-G (**A**), *TM6SF2* rs58542926-T (**B**), *GCKR* rs1260326-T (**C**) and *LYPLAL1* rs12137855-C (**D**). The grey area indicates the 95% confidence interval for the line. *R*^2^ is a measure of goodness of fit.](ddy124f2){#ddy124-F2}

Pairwise comparisons of the risk allele association profiles indicated that the effects of *GCKR* rs1260326-T and *LYPLAL1* rs12137855-C on circulating metabolites were highly similar (*R*^2^ = 0.71; [Supplementary Material, Fig. S4](#sup1){ref-type="supplementary-material"}). The overall pattern of metabolic effects of *TM6SF2* rs58542926-T correlated inversely with effects of both *GCKR* rs1260326-T and *LYPLAL1* rs12137855-C (*R*^2^ = 0.66, and *R*^2^ = 0.50, respectively; [Supplementary Material, Fig. S4](#sup1){ref-type="supplementary-material"}). The remaining correlations were weaker (0.19 ≤ *R*^2^ ≤ 0.24; [Supplementary Material, Fig. S4](#sup1){ref-type="supplementary-material"}).

To control for intercorrelation of the lipoprotein lipid traits, we further examined the correlations of metabolic effects using a subset of metabolic measures that represented independent clusters (*k* = 29) identified in the YFS metabolomics data ([Supplementary Material, Fig. S5](#sup1){ref-type="supplementary-material"}). The magnitudes of coefficients of determination were somewhat smaller than using the full data, as expected, but supported the findings of the primary analysis ([Supplementary Material, Fig. S6](#sup1){ref-type="supplementary-material"}).

Discussion
==========

We determined fatty liver-related metabolic changes in 1810 young and middle-aged Finns using 123 circulating metabolic measures assessed by NMR-based platform. We further compared the cross-sectional observations with metabolic signatures of known NAFLD risk alleles obtained from a publicly available metabolomics GWAS including up to 24 925 individuals ([@ddy124-B19]). The studied NAFLD risk alleles resulted in divergent metabolic association profiles. Despite *PNPLA3* rs738409-G being the strongest genetic risk factor for NAFLD ([@ddy124-B16]), it showed a null effect on circulating lipids and metabolites. Association profile of *GCKR* rs1260326-T was similar to the cross-sectional fatty liver associations, whereas *TM6SF2* rs58542926-T provided evidence to the opposite direction. The present results provide metabolomic evidence supportive to the recent findings about worsened metabolic features seen in association with obesity-linked NAFLD, but not with NAFLD arising due to risk alleles in *PNPLA3* and *TM6SF2* ([@ddy124-B17],[@ddy124-B22],[@ddy124-B23]). In turn, the more risk-prone metabolic association profile of the NAFLD risk allele in *GCKR* underlines the importance of proper regulation of glucose metabolism in both liver and cardiovascular health.

The metabolic association profiles reflect the biological functions of the risk alleles and suggest that the distinct molecular pathways giving rise to fatty liver may have divergent effects on circulating metabolome. The three pathways studied here are summarized in [Figure 3](#ddy124-F3){ref-type="fig"}. *Pathway I, excessive hepatic glucose levels and amplified lipogenesis*: *GCKR* rs1260326-T reduces GCKR ability to inhibit glucokinase resulting in enhanced hepatic glucose uptake, reduced fatty acid oxidation and increased lipogenesis ([@ddy124-B24]). Hepatic fatty acids can be converted to triglycerides to be stored in hepatic lipid droplets or secreted in VLDL particles ([@ddy124-B25]), where they can contribute respectively to development of steatosis or to levels of circulating lipids. Congruent with these observations, *GCKR* rs1260326-T increases risk of fatty liver ([@ddy124-B12],[@ddy124-B13]) and raises concentrations of all the apolipoprotein B containing lipoprotein particles and triglycerides in these particles, while circulating glucose level is marginally reduced ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 2). *GCKR* rs1260326-T associates also with elevated levels of glycolysis-related metabolites, circulating fatty acids and increased fatty acid saturation ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 2) compatible with the enhanced glycolytic and lipogenic activities promoted by this variant ([@ddy124-B24],[@ddy124-B26],[@ddy124-B27]). The amino acid association profile of *GCKR* rs1260326-T differs from the one of fatty liver in terms of concentrations of phenylalanine and tyrosine, both of which were increased in association with cross-sectional fatty liver but unaltered by the *GCKR* variant ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 1). Phenylalanine levels have been associated with cardiovascular disease risk ([@ddy124-B28]) while tyrosine is linked with incidence of diabetes ([@ddy124-B29]); the differences in the effects on the two biomarkers and on the two largest HDL subclasses and their lipids may be indicative to molecular pathways explaining why *GCKR* rs1260326-T rises concentrations of circulating lipids but does not seem to increase risk of cardiometabolic complications ([@ddy124-B30],[@ddy124-B31]) as fatty liver does. *LYPLAL1* rs12137855-C variant has a metabolically highly similar but statistically less robust effect than the *GCKR* rs1260326-T, as seen in highly correlated effect estimates of the two ([Supplementary Material, Fig. S4](#sup1){ref-type="supplementary-material"}). This finding advocates that LYPLAL1 may contribute to circulating and hepatic triglyceride levels by regulating hepatic glucose metabolism as does GCKR. This is supported by the discovery by Ahn *et al.* who showed that *LYPLAL1* inhibition leads to increase in glucose production in human, rat and mouse hepatocytes ([@ddy124-B32]).

![Relation of the studied NAFLD risk alleles to the main pathways in hepatic triglyceride partitioning. Liver converts carbohydrates to lipids in *de novo* lipogenesis. Newly synthesized fatty acids enter to the hepatic fatty acid pool which is also supplied by dietary fats and circulating free fatty acids derived mostly from adipose tissue lipolysis or lipoprotein lipase spillover ([@ddy124-B1],[@ddy124-B25]). Fatty acids can be partitioned to oxidative pathway or esterified to triglycerides that can be stored in hepatic lipid droplets or used for VLDL production to be secreted from the liver ([@ddy124-B1],[@ddy124-B25]). The hepatic fatty acid pool is located upstream from the lipid storage and secretion pathways, and thus abundance in hepatic fatty acids can contribute to both development of fatty liver and increased production of VLDL. In line with this, *GCKR* rs1260326-T that enhances the lipogenic pathway by providing more substrates for fatty acid biosynthesis ([@ddy124-B24]) increases risk of fatty liver ([@ddy124-B12],[@ddy124-B13]) and raises concentrations of all the apoB containing lipoproteins and lipids in these particles while circulating glucose level is marginally reduced ([Fig. 1](#ddy124-F1){ref-type="fig"}). *LYPLAL1* may be functioning on the same hepatic glucose metabolism and lipogenesis related pathway, as the metabolic effects of *GCKR* rs1260326-T and *LYPLAL1* rs12137855-C are highly similar ([Supplementary Material, Fig. S4](#sup1){ref-type="supplementary-material"}). On the contrary, *TM6SF2* rs58542926-T impairs the secretory pathway leading to lipid accumulation into the liver ([@ddy124-B14]) and reduction in levels of circulating lipids and lipoproteins ([Fig. 1](#ddy124-F1){ref-type="fig"}). *PNPLA3* rs738409-G, in turn, enhances triglyceride accumulation to the storage pool by diminishing triglyceride hydrolysis to fatty acids ([@ddy124-B41],[@ddy124-B42]), but does not directly contribute to VLDL secretion, and thus conveys no major consequences to circulation ([Fig. 1](#ddy124-F1){ref-type="fig"}).](ddy124f3){#ddy124-F3}

*Pathway II, reduced VLDL secretion*: TM6SF2 contributes to VLDL secretion from the liver ([@ddy124-B33]). In mice, knockdown of *Tm6sf2* triplicates hepatic triglyceride content while blood lipids are decreased ([@ddy124-B14]). Conversely, overexpression of human *TM6SF2* in mice increases serum lipids levels ([@ddy124-B15]). The NAFLD risk allele *TM6SF2* rs58542926-T is a loss-of-function variant resulting in a misfolded protein undergoing accelerated degradation ([@ddy124-B14]). The mechanism leading to impaired lipidation, subsequent degradation and thus reduced secretion of VLDL particles seem to be due to deficiency in polyunsaturated phosphatidylcholines in *TM6SF2* rs58542926-T carriers ([@ddy124-B34]). This allele associates with reduced concentrations of multiple lipid species in circulation while it has no influence on qualitative measures of circulating lipids, such as fatty acid saturation ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 5). The inverse associations between *TM6SF2* rs58542926-T and all the circulating VLDL particle subclass concentrations, lipid species within the lipoprotein subclasses, as well as apolipoprotein B concentration are supportive for *TM6SF2* rs58542926-T disturbing both lipidation and secretion of VLDL particles in humans. This differs from the observation of a study with *Tm6sf2*^−/−^ mice, which provided evidence that mouse Tm6sf2 is required for lipidation of VLDL, but lack of it does not influence VLDL secretion ([@ddy124-B35]). Our results are compatible with lipidomic effects of *TM6SF2* rs58542926-T ([@ddy124-B36]) and studies that associated this variant with a favourable plasma lipid profile and cardioprotective effect at the expense of increased risk for progressive NAFLD ([@ddy124-B17],[@ddy124-B37]). Interestingly, *TM6SF2* rs58542926-T associates with lower level of glycoprotein acetylation, a marker for inflammation ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 5), indicating that its cardioprotective effect is not limited only to lipoprotein and lipid metabolism. However, the same allele has been associated with increased risk of type 2 diabetes ([@ddy124-B38]) underlining its complex effect on systemic metabolism.

*Pathway III, impairment of triglyceride mobilization from hepatic lipid storage*: PNPLA3 is located in the endoplasmic reticulum and lipid droplet membranes in human hepatocytes and shows both acyltransferase and hydrolase activities on glycerolipids ([@ddy124-B39]). Despite the intensive research on the topic, the exact mechanism of how the common variant rs738409-G promotes development of liver disease is not clear. Several studies advocate that the variant inhibits triglyceride hydrolysis ([@ddy124-B39],[@ddy124-B41],[@ddy124-B42]) possibly arising from accumulation of inactive PNPLA3 on lipid droplets disturbing mobilization of lipids ([@ddy124-B43],[@ddy124-B44]). Some studies have shown that this risk allele does not influence common blood lipid traits, triglyceride profile, nor glucose homeostasis ([@ddy124-B10],[@ddy124-B11],[@ddy124-B22]), while some studies have associated rs738409-G with lower lipid levels and protection from cardiovascular disease ([@ddy124-B45],[@ddy124-B46]). The present results extend the findings of previous studies from common blood lipid traits to detailed fatty acid, amino acid and lipoprotein subfraction measures, and confirms the perception that rs738409-G has only minimal, if any, contribution to the metabolic traits in circulation ([Fig. 1](#ddy124-F1){ref-type="fig"}, panel 4). Our results are compatible with a mouse model where *Pnpla3*^148M/M^ knock-in mice show no differences in levels of circulating lipids and glucose in comparison with wild-type mice regardless of the increase in liver triglycerides ([@ddy124-B43]). These observations advocate that hepatic lipid accumulation can be neutral for circulatory changes and that the strong cross-sectional associations are largely due to lifestyle-related aspects such as dietary factors, excess energy intake or sedentary lifestyle. Dietary lipids and sugars and adipose tissue-derived fatty acids supply the fatty acid pool upstream from the lipid storage and secretion pathways ([@ddy124-B25]), and consequently overnutrition could contribute to both fatty liver development as well as altered metabolic profile. The importance of nutritional factors is highlighted also when determining genetic risk for NAFLD, as adiposity has been shown to amplify the effect of the NAFLD risk alleles in *PNPLA3, TM6SF2* and *GCKR* ([@ddy124-B47]).

This study has some limitations. We examine a limited number of NAFLD risk alleles while there are multiple other genetic pathways contributing to pathogenesis of NAFLD ([@ddy124-B16],[@ddy124-B48],[@ddy124-B49]). However, the risk alleles in *PNPLA3, TM6SF2* and *GCKR* are important determinants of liver fat content and thus the current study setting covers some of the fundamental pathways involved in NAFLD pathogenesis ([@ddy124-B13],[@ddy124-B14]). The role of the *LYPLAL1* variant in NAFLD pathogenesis needs additional assessment; however, the current results provide a novel insight into LYPLAL1 function, which potentially helps in directing the focus of further studies. Regarding the cross-sectional associations, ultrasound lacks sensitivity to detect mild steatosis ([@ddy124-B50]), leading to conservative association magnitudes. Despite the known deficiencies, ultrasound is a feasible method to be used for liver screening in a large population study. Also, the study populations compose of relatively young European individuals, and the present findings would need to be confirmed in other demographic groups. A recent study with ∼300 000 individuals detected a small effect for the *PNPLA3* risk allele ([@ddy124-B46]), and thus it is likely that with a larger sample size we would also see a small effect. However, when considering the great NAFLD risk increase associated with this variant ([@ddy124-B12]), the relative effect on the circulating metabolic measures is minute. The strength of the metabolomics panel used is in detailed lipoprotein metabolism, while alternative techniques for metabolic profiling, such as a more detailed lipidomics platform ([@ddy124-B51]), may reveal other biomarker changes associated with NAFLD induced by the studied risk alleles. The metabolic traits captured with the current panel include multiple known biomarkers of cardiometabolic diseases ([@ddy124-B52],[@ddy124-B53]). Importantly, these biomarkers show strong associations with fatty liver, and the studied risk alleles show divergent effects on the corresponding measures underlining the heterogeneous nature of fatty liver.

The present study illustrates how open-access omics data can be utilized in evaluation of molecular mechanisms complex traits, such as NAFLD. The divergence in the direction of the risk allele association profiles advocates that different molecular pathways leading to NAFLD may have alternate effects on circulating lipids and other metabolites. We highlight the minimal metabolic effect of the strongest genetic determinant of NAFLD, *PNPLA3* rs738409-G, and the cardioprotective effect of the *TM6SF2* rs58542926-T on circulating lipids. Our findings suggest that, despite the strong population level associations, hepatic lipid accumulation by itself does not necessarily increase the risk of hyperlipidemia associated with cardiometabolic complications.

Materials and Methods
=====================

Study population
----------------

The Cardiovascular risk in Young Finns Study (YFS) is a population-based follow-up study started in 1980. In 2011, 2046 individuals aged 34--49 years participated to ultrasound imaging of the liver (Acuson Sequoia 512, Acuson, Mountain View, CA, USA). In total, fatty liver was diagnosed in 18.6% (*N* = 372) of the participants. The population and ultrasound imaging of the liver are described in more detail by Kaikkonen *et al.* ([@ddy124-B4]) and Suomela *et al.* ([@ddy124-B54]). After exclusion of pregnant women and individuals using lipid lowering medication or oral contraceptives, the total number of individuals included in the analysis was 1810 (*N*~fatty\ liver~ = 338). The study was approved by the local Ethics Committee and written informed consent was obtained from all the participants.

Metabolic effects of NAFLD risk alleles
---------------------------------------

Effect estimates of *PNPLA3* rs738409-G, *GCKR* rs1260326-T, *GCKR* rs780094-T, *TM6SF2* rs58542926-T, *NCAN* rs2228603-T and *LYPLAL1* rs12137855-C on the metabolic measures were acquired from a GWAS performed using 14 European cohorts in up to 24 925 individuals ([@ddy124-B19]). The mean age and BMI of the participants per cohort ranged from 23.9 to 61.3 years and from 23.1 to 28.2 kg/m^2^ with the whole sample means being 46.3 years and 26.0 kg/m^2^. The genotyping methods are described in the original publication ([@ddy124-B19]).

Risk allele frequencies and odds ratios to NAFLD for the studied loci are described in [Table 2](#ddy124-T2){ref-type="table"}. To facilitate comparison of the risk allele associated metabolic changes relative to NAFLD risk increase, the risk allele effects and related 95% confidence intervals were scaled with respect to the log(odds ratio) on histologic NAFLD associated with the corresponding locus in a large-scale GWAS ([@ddy124-B12]). Scaling the metabolic associations with respect to a common factor allows evaluation of the effect similarities regardless of the magnitude of the absolute effect, which can be helpful when the study interest is on the metabolic pathways involved rather than in the absolute effects. The same principle has been applied for example in a study comparing metabolic effects of statin treatment versus genetic inhibition of HMGCR, where the large difference in the absolute effects of statins and *HMGCR* rs12916 genotype was overcome by scaling the metabolic effects to the magnitude on LDL-C lowering ([@ddy124-B55]). *P*-values for the genetic effects were derived directly from the metabolomics GWAS ([@ddy124-B19]). Table 2.Description of NAFLD risk increasing genotypes extracted from the open access data**NAFLD GWAS by Speliotes *et al.* (**[@ddy124-B12]**)Metabolomics GWAS by Kettunen *et al.* (**[@ddy124-B19]**)**GenedbSNP referenceEALocus OR for histologic NAFLD (95% CI)EAFEAF*PNPLA3*rs738409G3.24 (2.83--3.72)0.230.23*NCAN*rs2228603T1.90 (1.55--2.34)0.070.07*\*TM6SF2*rs58542926TNA0.06*LYPLAL1*rs12137855C1.21 (1.02--1.43)0.790.74*GCKR*rs780094T1.18 (1.05--1.34)0.390.37*\*GCKR*rs1260326TNA0.36[^3][^4]

Metabolic profiling
-------------------

Metabolic profiling of all samples included were assessed using a nuclear magnetic resonance (NMR) metabolomics platform described in ([@ddy124-B19]) and reviewed in ([@ddy124-B52],[@ddy124-B53]). To determine the cross-sectional metabolic associations of fatty liver, we utilized 123 metabolic measures representing a broad molecular signature of systemic metabolism ([Supplementary Material, Table S1](#sup1){ref-type="supplementary-material"}).

Statistical analyses
--------------------

All analyses were done using R version 3.2.2. Due to the correlation of the metabolic measures, the number of independent tests performed is lower than the total number of 123 metabolic traits examined. We considered statistical significance at  \< 0.0004 (0.05/22/5), where 22 is the number of principal components explaining 95% of the variation in the NMR metabolomics data ([@ddy124-B19]) and five is the number of analyses conducted.

### Cross-sectional associations

Linear regression models were fitted to determine the cross-sectional associations of fatty liver with each of the metabolic measures in the YFS population. To enable the comparison of cross-sectional and genetic effect estimates, the data processing and analysis model were done correspondingly to Kettunen *et al.* ([@ddy124-B19]): the metabolic phenotypes were adjusted for age, sex and 10 first genetic principal components preceding the analysis, and the resulting residuals were transformed to normal distribution by inverse rank-based normal transformation. The adjusted and transformed metabolic phenotypes were used as outcomes in the equations and fatty liver served as a categorical variable (fatty liver vs. no fatty liver). Secondary analyses were conducted with additional adjustment for alcohol consumption or BMI to evaluate the possible contribution of alcoholic fatty liver and obesity to the observed metabolic changes. The genetic principal components were calculated using PLINK software on linkage disequilibrium pruned markers after removing variants with more than 5% missing data and poorly genotyped samples with more than 5% missing data.

### Comparisons of the metabolic association profiles

The overall resemblance between the risk alleles and fatty liver effects on metabolites was determined by a linear fit of each of the risk allele association profile versus cross-sectional fatty liver association profile ([@ddy124-B55]). In addition, the linear fit of all the pairs of the risk allele association profiles were determined to identify alleles with similar metabolic effects informing about gene products functioning in related biological pathways. This method was also used to ensure that the metabolic profiles of the NAFLD risk alleles *GCKR* rs780094-T and *NCAN* rs2228603-T correspond to ones of *GCKR* rs1260326-T and *TM6SF2* rs58542926-T that have been identified as the functional variants in *GCKR* and *NCAN*/*TM6SF2* loci, respectively ([@ddy124-B13]).

Due to the correlated nature of the lipoprotein lipid measures, we completed sensitivity analyses on the correlation tests with a subset of metabolic measures: we first assessed independent clusters of the metabolic measures in the YFS population using hierarchical clustering and gap statistics in factoextra R package, and then selected one metabolic measure per identified cluster for re-evaluation of the resemblance of the metabolic effects.
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[^1]: One unit equals to 12 g of alcohol.

[^2]: Values are mean ± SD, or absolute *N* count and corresponding percentage. YFS, Young Finns Study.

[^3]: DNA sequence variants studied in the present study were associated with computed tomography characterized steatosis and biopsy-proven NAFLD involving liver inflammation and fibrosis by Speliotes *et al.* ([@ddy124-B12]). The functional variants explaining the NAFLD associations of *NCAN* rs2228603 and *GCKR* rs780094 are denoted separately (\*). To achieve coherency, the *NCAN* locus is referred as *TM6SF2* throughout the paper.

[^4]: *PNPLA3*, Patatin-like phospholipase domain containing *3*, NM_025225; *NCAN*, Neurocan, NM_004386; *TM6SF2*, Transmembrane 6 superfamily member 2, NM_001001524; *LYPLAL1*, Lysophospholipase-like 1, NM_001350628; *GCKR*, Glucokinase regulator, NM_001486; SNP, single-nucleotide polymorphism; EA, effect allele; OR, odds ratio; NAFLD, non-alcoholic fatty liver disease; EAF, effect allele frequency; NA, not available.
